A role for macroautophagy in protection against 4-hydroxytamoxifen–induced cell death and the development of antiestrogen resistance
Tóm tắt
Từ khóa
Tài liệu tham khảo
Jordan VC. Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nature 2007;7:46–53.
Osborne CK, Schiff R. Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol 2005;23:1616–22.
Caldon CE, Daly RJ, Sutherland RL, et al. Cell cycle control in breast cancer cells. J Cell Biochem 2006;97:261–74.
Sutherland RL, Musgrove EA. Cyclins and breast cancer. J Mammary Gland Biol Neoplasia 2004;9:95–104.
Bouker KB, Skaar TC, Fernandez DR, et al. Interferon regulatory factor-1 mediates the proapoptotic but not cell cycle arrest effects of the steroidal antiestrogen ICI 182,780 (faslodex, fulvestrant). Cancer Res 2004;64:4030–39.
El Etreby MF, Liang Y, Wrenn RW, et al. Additive effect of mifepristone and 4-hydroxytamoxifen on apoptotic pathways in MCF-7 human breast cancer cells. Breast Cancer Res Treat 1998;51:149–68.
Thiantanawat A, Long BJ, Brodie AM. Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens. Cancer Res 2003;63:8037–50.
Kallio A, Zheng A, Dahllund J, et al. Role of mitochondria in tamoxifen-induced rapid death of MCF-7 breast cancer cells. Apoptosis 2005;10:1395–410.
Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998;351:1451–67.
Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992;399:1–15.
Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371–88.
Veronesi U, Maisonneuve P, Rotmensz N, et al. Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high risk women. J Natl Cancer Inst 2003;95:160–5.
Normanno N, DiMaio M, DeMaio E, et al. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocrine Related Cancer 2005;12:721–47.
Miller WR, Bartlett JMS, Canney, et al. Hormonal therapy for postmenopausal breast cancer: the science of sequencing. Breast Cancer Res Treat 2007;103:149–60.
ATAC Trialist's Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60–2.
BIG1-98 Collaborative Group. A comparison of letrozole with tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747–57.
Clarke R, Leonessa F, Welch JN, et al. Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev 2001;53:25–71.
Ariazi EA, Ariazi JL, Cordera F, et al. Estrogen receptors as therapeutic targets in breast cancer. Curr Top Med Chem 2006;6:181–202.
Nicholson RI, Johnston SR. Endocrine therapy, current benefits and limitations. Breast Cancer Res Treat 2005;93:S3–10.
Perey L, Paridaens R, Hawle H, et al. Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK21/00). Ann Oncol 2007;18:64–9.
Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation. Science 2000;290:1717–21.
Lum JJ, Bauer DE, Kong M, et al. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 2005;120:237–48.
Debnath J, Baehrecke EH, Kroemer G. Does autophagy contribute to cell death? Autophagy 2005;1:66–74.
Liang XH, Jackson S, Seaman M, et al. Induction of autophagy and inhibition of tumorigenesis of beclin 1. Nature 1999;402:672–6.
Bursch W, Ellinger A, Kienzl H, et al. Active cell death induced by the anti-estrogens tamoxifen and ICI164 384 in human mammary carcinoma cells (MCF-7) in culture: the role of autophagy. Carcinogenesis 1996;17:1595–607.
Gaddy VT, Barrett JT, Delk JN, Kallab AM, Porter AG, Schoenlein PV. Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells. Clin Cancer Res 2004;10:5215–25.
Schoenlein PV, Hou M, Samaddar JS, et al. Downregulation of retinoblastoma protein is involved in the enhanced cytotoxicity of 4-hydroxytamoxifen plus mifepristone combination therapy versus antiestrogen monotherapy of human breast cancer. Int J Oncol 2007;31:643–55.
Dimri GP, Lee X, Basile G, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 1995;92:9363–7.
Biederbick A, Kern HF, Elsasser HP. Monodansylcadaverine (MDC) is a specific in vivo marker for autophagic vacuoles. Eur J Cell Biol 1995;66:3–14.
Munafo DB, Colombo MI. A novel assay to study autophagy: regulation of autophagosome vacuole size by amino acid deprivation. J Cell Sci 2001;114:3619–29.
Seglen PO, Gordon PB. 3-Methyladenine: specific inhibitor of autophagic/lysosomal protein degradation in isolated rat hepatocytes. Proc Natl Acad Sci U S A 1982;79:1889–92.
Kuncithapautham K, Rohrer B. Apoptosis and autophagy in photoreceptors exposed to oxidative stress. Autophagy 2007;3:433–41.
Jia L, Dourmashkin RR, Allen PD, Gray AB, Newland AC, Kelsey SM. Inhibition of autophagy abrogates tumour necrosis factor α induced apoptosis in human T-lymphoblastic leukaemic cells. Br J Haematol 1997;98:673–85.
Orth K, Chinnaiyan AM, Garg M, Froelich CJ, Dixit VM. The CED-3/ICE-like protease Mch2 is activated during apoptosis and cleaves the death substrate lamin A. J Biol Chem 1996;271:16443–6.
Schoenlein PV. The role of gene amplification in drug resistance. In: Ozols, RF, Goldstein LJ, editors. Anticancer drug resistance: advances in molecular and clinical research. Norwell (MA): Kluwer Academic Publishers; 1995. pp. 167–200.
Kisanga ER, Gjerde J, Guerrieri-Gonzaga A, et al. Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial. Clin Cancer Res 2004;10:2336–43.
Dragan YP, Fahey S, Nuwaysir E, et al. The effect of tamoxifen and two of its non-isomerizable fixed-ring analogs on multistage rat hepatocarcinogenesis. Carcinogenesis 1996;7:585–94.
Kabeya Y, Mizushima N, Ueno T, et al. LC3, a mammalian homologue of yeast Apg8, is localized in autophagosome membranes after processing. EMBO J 2000;19:5720–8.
Yoshimori T, Yamamoto A, Moriyama Y, et al. Bafilomycin A1, a specific inhibitor of vacuolar-type H+-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells. J Biol Chem 1991;266:17707–12.
Janicke RU, Sprengart ML, Wati MR, et al. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 1998;273:9357–60.
Paglin S, Hollister T, Delohery T, et al. A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Res 2001;61:439–44.
Boya P, Gonzalez-Polo RA, Casares N, et al. Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol 2005;25:1025–40.
Heymann D. Autophagy: a protective mechanism in response to stress and inflammation. Curr Opin Investig Drugs 2006;7:443–50.
Sato K, Tsuchihara K, Fujii S, et al. Autophagy is activated in colorectal cancer cells and contributes to the tolerance to nutrient deprivation. Cancer Res 2007;67:9677–84.
Amaravadi RK, Yu D, Lum JJ, et al. Autophagy inhibition enhances therapy-induced apoptosis in a MYC-induced model of lymphoma. J Clin Invest 2007;117:326–36.
Abedin MJ, Wang D, McDonnell MA, et al. Autophagy delays apoptotic death in breast cancer cells following DNA damage. Cell Death Differ 2005;3:500–10.